Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Shareholder Loan and Related Party Transaction

Oxford, UK - 19 December 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform announces that it has entered a loan agreement with Vulpes Testudo Fund (the "Loan"). The Loan will provide up to £1 million in working capital, to enable the Company to continue to pursue funding options.

The Loan is interest free and may be drawn down as required by the Company. The amount owed to Vulpes under the Loan agreement will be subordinate to amounts owed to other creditors. The Loan is unsecured and is due to be repaid within 90 days.

Together with the Vulpes Life Sciences Fund, Vulpes Testudo Fund is interested in a total of 29,653,978 ordinary shares, representing 9.4% of the current issued share capital. Each of the funds is part of Vulpes Investment Management, which is controlled by Non-Executive Director Stephen Diggle. As a result, the Loan is considered a related party transaction under AIM Rule 13.

Having consulted with the Company's Nominated Adviser, Shore Capital, the Board (except for Stephen Diggle), considers that the terms of the Loan as set out above are fair and reasonable as far as the Company's shareholders are concerned.

The Loan provides the Company with additional working capital and cash runway, but the Company will still need to source additional funding in early Q1 2025. A further update will be provided as appropriate.

Matthew Wakefield, Non-Executive Chairman, commented: "We are grateful to Vulpes for supporting the Company in this way. The loan facility provides the Company and its incoming Executive Chairman Iain Ross with additional time to secure further equity funding."

-Ends-

For more information:

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.